Despite recent advances with therapies such as sodium-glucose co-transporter 2 inhibitors (SGLT2i) (Tsukamoto et al. 2022; Yau et al. 2022), mineralocorticoid receptor antagonists (Tsukamoto et al. 2022; Amornritvanich et al. 2024), and GLP-1 receptor agonists (Badve et al. 2025; Abasheva et al. 2024), which have demonstrated efficacy in slowing chronic kidney disease (CKD) progression, reducing kidney inflammation, and lowering the risk of cardiovascular events, there remains a critical unmet need for treatments that can fully restore kidney function or reverse established tissue fibrosis. This evidence concerns the gene NR3C2 and chronic kidney disease.